Frontlight ResearchEarly access
CompletedPhase 4
SePkLin Study: Pragmatic, Multicenter, Randomized, Controlled Clinical Trial in Patients with Sepsis to Evaluate the Safety and Efficacy of Personalized Pk/Pd Dosing Versus Standard Dosing of LINezolid.
Key facts
- Who runs it
- Fundacion Instituto De Investigacion Sanitaria De Santiago De Compostela
- Where
- Spain2 sites in 1 countryChoose a country to see its sites
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 692 people enrolled
- Started
- 2 Apr 2024
- Ended
- 4 Mar 2026
- Type of study
- Interventional
- Record updated
- 2 August 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Adult patients (18 years and older) receiving linezolid
- Diagnosis of sepsis (SOFA scale ≥ 2 points or in the case of chronic organ dysfunction, increase of 2 points compared to the baseline score)
- Patients have started antibiotic treatment with linezolid according to usual clinical practice
Who cannot take part
- Known allergy or hypersensitivity to linezolid
- Interruption of treatment before the first blood sample
- Pregnant or nursing women
- Patients will be excluded if they are already in any other intervention trials
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective of the study is to demonstrate the superiority of personalized linezolid dosing based on PK/PD by evaluating the incidence of thrombocytopenia in both treatment groups.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 2 August 2024